NCT04680468View on ClinicalTrials.gov

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL

Enrollment

47

Participants

Timeline

Start Date

June 2, 2021

Primary Completion Date

July 11, 2026

Study Completion Date

July 11, 2026

Conditions

Myeloma

Interventions

DRUG

Belantamab mafodotin

2.5 mg/kg IV

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Pennsylvania

OTHER